Acadia Pharma (ACAD) Tops Q2 EPS by 12c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $27.74 +0.22%
Revenue Growth %: +19.1%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +19.1%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of $0.18, $0.12 better than the analyst estimate of $0.06. Revenue for the quarter came in at $307.96 million versus the consensus estimate of $296.02 million.
FY 2026 Outlook:-
Revenue between $1.24 to $1.30 billion vs consensus $1.24 billion.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Microsoft plans data center push to triple its computing power - Bloomberg
- UBS Downgrades Ypsomed Holding AG (YPSN:SW) to Neutral
- JPMorgan Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
